Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Rein Therapeutics Inc <RNTX.OQ> expected to post a loss of 17 cents a share - Earnings Preview
Rein Therapeutics Inc RNTX.OQ RNTX.O is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Rein Therapeutics Inc is for a loss of 17 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Rein Therapeutics Inc is $6.00, about 633.9% above its last closing price of $0.82
This summary was machine generated August 10 at 20:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering